A Precision Strike to Treat Prostate Cancer
An antibody that targets a prostate cell protein shows potential for designing safer, more effective prostate cancer therapies.
In the Lab
More Precise Imaging of Prostate Cancer Could Give Insight into Drug Effectiveness
An antibody that targets a protein specific to prostate cells can be used to image prostate cancer more clearly and indicate how well drugs are working.
In the Clinic
Bone Scan Index May Help Determine Response to Prostate Cancer Treatment
Researchers at Memorial Sloan Kettering have shown the usefulness of a scale called the Bone Scan Index (BSI) for determining whether some prostate cancer patients are responding to therapy.
Novel Cancer-Targeting Investigational Nanoparticle Receives FDA IND Approval for First-In-Human Trial
Researchers at Memorial Sloan Kettering Cancer Center's Nanotechnology Center, along with collaborators at Cornell University and Hybrid Silica Technologies, have received approval for their first Investigational New Drug Application (IND) from the US Food and Drug Administration (FDA) for an ultrasmall silica inorganic nanoparticle platform for targeted molecular imaging of cancer, which may be useful for cancer treatment in the future.